Certara/$CERT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Certara
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
- Ticker
- $CERT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,546
- Headquarters
- Radnor, United States
- Website
- www.certara.com
Certara Metrics
BasicAdvanced
$1.7B
-
-$0.43
1.41
-
Price and volume
Market cap
$1.7B
Beta
1.41
52-week high
$11.88
52-week low
$4.45
Average daily volume
2.7M
Financial strength
Current ratio
2.551
Quick ratio
2.441
Long term debt to equity
0.306
Total debt to equity
0.312
Interest coverage (TTM)
0.60%
Profitability
EBITDA (TTM)
88.349
Gross margin (TTM)
61.61%
Net profit margin (TTM)
-16.22%
Operating margin (TTM)
4.27%
Effective tax rate (TTM)
-57.80%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
0.51%
Return on equity (TTM)
-2.21%
Valuation
Price to revenue (TTM)
4.127
Price to book
1.74
Price to tangible book (TTM)
-17.36
Price to free cash flow (TTM)
31.897
Free cash flow yield (TTM)
3.14%
Free cash flow per share (TTM)
0.345
Growth
Revenue change (TTM)
11.09%
Earnings per share change (TTM)
-997.74%
3-year revenue growth (CAGR)
6.20%
3-year earnings per share growth (CAGR)
53.42%
What the Analysts think about Certara
Analyst ratings (Buy, Hold, Sell) for Certara stock.
Analyst projections of the future price of Certara stock.
Bulls say / Bears say
Software revenue rose 4% and software bookings rose 9% in Q2, outpacing overall revenue growth of 1%. That points to stronger demand in Certara’s software business, although it still needs to convert into faster total growth. (Certara)
Certara’s collaboration with NVIDIA aims to combine its biosimulation models, data and scientific expertise with NVIDIA’s AI toolkit. If customers adopt these capabilities, they could make Certara’s platform more valuable and support future growth. (Certara)
The sale of the regulatory and medical writing business and a workforce reduction affecting about 5% of employees are intended to sharpen Certara’s focus and generate roughly $13 million in annualised savings. Those savings could help fund investment in its core businesses and support margins. (Certara)
Q2 services revenue fell 3% and services bookings fell 6%, while the full-year revenue outlook is only 0%–4% growth. Overall performance therefore depends heavily on software momentum and a recovery in services. (Certara)
Certara reported a $6.1 million Q2 net loss, compared with net income a year earlier, and adjusted EBITDA declined 3%. The company’s adjusted EBITDA margin outlook is 29%–31%, leaving execution on costs and profitability important to the investment case. (Certara)
Recent analysis said weak free cash flow has yet to improve alongside software bookings, raising a concern about how quickly bookings translate into cash. Certara also cautions that bookings may not reliably predict future revenue. (Seeking Alpha, SEC)
Data summarised monthly by Lightyear AI. Last updated on 24 Oct 2026.
Certara Financial Performance
Revenues and expenses
Certara Earnings Performance
Company profitability
Upcoming events
No upcoming events
Certara News
AllArticlesVideos
Funds containing Certara
AllUSDEURGBP
Fund name | Fund size | $CERT weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.13% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.13% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.13% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.07% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.